PI3Kδ activation, IL-6 overexpression, and CD37 loss cause resistance to naratuximab emtansine in lymphomas.
Arribas AJ, Napoli S, Gaudio E, Herbaux C, Cannas E, Tarantelli C, Bordone-Pittau R, Cascione L, Munz N, Aresu L, Sgrignani J, Rinaldi A, Kwee I, Rossi D, Cavalli A, Zucca E, Stussi G, Stathis A, Sloss C, Davids MS, Bertoni F.
Arribas AJ, et al. Among authors: aresu l.
Blood Adv. 2024 Dec 24;8(24):6268-6281. doi: 10.1182/bloodadvances.2023012291.
Blood Adv. 2024.
PMID: 39374583